ReviewNeuro-oncology advances2025
Immunologic specificity in glioblastoma: Antigen discovery and translational implications.
Review in Neuro-oncology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Microbiota-Neuroinflammation Crosstalk in Primary Brain Tumors: Focus on Glioblastoma.Brain and behavior · 2026Review
- Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.NPJ precision oncology · 2026Review
- Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have highlighted the therapeutic potential of targeting tumor antigens (TAs) in glioblastoma (GBM). Several classes of TAs, such as tumor-associated, cancer testis, and tumor-specific antigens, have proven to be immunogenic and used safely in vaccines. Many of these vaccines have focused on tumor-associated or cancer testis antigens. However, tumor-specific antigens (TSA) present an ideal target due to the lack of tolerance and exclusive tumor expression, mitigating the risk of off-target effects. Most research on TSAs in GBM has aimed to uncover neoantigens, yet the dearth of shared neoantigens as well as the cost and labor-intensive process of identifying personal neoantigens have acted as barriers to treatment. A better understanding of the individual antigens spanning all three TA classes is important to improve the design of GBM antigen therapies and understand, fundamentally, the nature of immunologic specificity in glioma. We review the antigen classes in all cancers and how TAs are discovered. Then, we focus on the unique properties of GBM and the antigens that have been identified and used for therapy in GBM. Finally, we discuss translational considerations for future antigen-targeted treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.